• Trade
  • Markets
  • Copy
  • Contests
  • News
  • 24/7
  • Calendar
  • Q&A
  • Chats
Screeners
SYMBOL
LAST
ASK
BID
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6917.82
6917.82
6917.82
6993.09
6862.05
-58.62
-0.84%
--
DJI
Dow Jones Industrial Average
49240.98
49240.98
49240.98
49653.13
48832.78
-166.67
-0.34%
--
IXIC
NASDAQ Composite Index
23255.18
23255.18
23255.18
23691.60
23027.21
-336.92
-1.43%
--
USDX
US Dollar Index
97.200
97.280
97.200
97.510
97.120
-0.210
-0.22%
--
EURUSD
Euro / US Dollar
1.18198
1.18211
1.18198
1.18199
1.18075
+0.00023
+ 0.02%
--
GBPUSD
Pound Sterling / US Dollar
1.37005
1.37020
1.37005
1.37009
1.36821
+0.00041
+ 0.03%
--
XAUUSD
Gold / US Dollar
4962.49
4962.93
4962.49
4967.35
4946.04
+16.24
+ 0.33%
--
WTI
Light Sweet Crude Oil
63.475
63.505
63.475
63.499
63.455
-0.159
-0.25%
--

Community Accounts

Signal Accounts
--
Profit Accounts
--
Loss Accounts
--
View More

Become a signal provider

Sell trading signals to earn additional income

View More

Guide to Copy Trading

Get started with ease and confidence

View More

Signal Accounts for Members

All Signal Accounts

Best Return
  • Best Return
  • Best P/L
  • Best MDD
Past 1W
  • Past 1W
  • Past 1M
  • Past 1Y

All Contests

  • All
  • Trump Updates
  • Recommend
  • Stocks
  • Cryptocurrencies
  • Central Banks
  • Featured News
Top News Only
Share

Colombia Central Bank Sees 2027 Inflation At 3.7%, 6.3% In 2026

Share

Federal Reserve Governor Milan Has Resigned From The White House

Share

SPDR Gold Holdings Down 0.34%, Or 3.72 Tonnes

Share

The US AI Software Pioneer Index Closed Down 5.22% At 101.34 Points. US Stocks Fell Sharply In Early Trading And Continued To Fluctuate At Low Levels After 23:00 Beijing Time

Share

Government: Peru's Exports Rose 21% From 2024 To Hit Record $90.082 Billion In 2025

Share

USA Treasury Issues License Authorizing Supply Of USA Diluents To Venezuela, Administration Official Tells Reuters

Share

Ukrainian Energy Minister Says Kyiv Power Plant Badly Damaged

Share

Rubio Discussed Formalizing Bilateral Cooperation On Critical Minerals Exploration, Mining, And Processing With Indian External Affairs Minister - State Department

Share

US President Trump Reiterated His Zero-sum Game Against The Health Insurance Industry

Share

Colombian President Petro, After Feud With Trump, Says White House Meeting Went Well

Share

US President Trump: Millions Of Barrels Of Venezuelan Oil Seized Are Being Shipped To Houston, Texas

Share

(US Stocks) The Philadelphia Gold And Silver Index Closed Up 4.63% At 398.43 Points. (Global Session) The NYSE Arca Gold Miners Index Rose 4.29% To 2815.40 Points. (US Stocks) The Materials Index Closed Up 4.04%, And The Metals & Mining Index Closed Up 5.35%

Share

On Tuesday (February 3), In Late New York Trading, Spot Silver Rose 7.36% To $85.0929 Per Ounce, Reaching A Daily High Of $89.1655 At 21:46 Beijing Time. Comex Silver Futures Rose 11.05% To $85.505 Per Ounce, Reaching A Daily High Of $89.100 At 21:46. Comex Copper Futures Rose 4.47% To $6.0960 Per Pound, Experiencing A Significant Upward Surge At 14:00 – After A Period Of Low-level Consolidation, They Subsequently Traded In A High-level Range. Spot Platinum Rose 4.08%, And Spot Palladium Rose 1.82%

Share

Trump: Federal Government Should Get Involved In Elections

Share

Trump: Working On Sanction With Colombia

Share

Trump: We Are Negotiating With Iran Right Now

Share

Data From The American Petroleum Institute (API) Shows That U.S. Crude Oil Inventories Fell By 11.079 Million Barrels Last Week, Compared With An Increase Of 247,000 Barrels The Previous Week

Share

US Magnificent 7 Closing Report | On Tuesday (February 3), The Magnificent 7 Index Fell 1.68% To 203.68 Points, Mainly Fluctuating At Low Levels Throughout The Day. The "mega-cap" Tech Stock Index Fell 1.90% To 387.08 Points, Also Fluctuating At Low Levels For Most Of The Day

Share

The S&P 500 Fell 58.63 Points, Or 0.84%, To 6917.81. The Dow Jones Industrial Average Fell 166.67 Points, Or 0.34%, To 49240.99. The Nasdaq Composite Fell 336.922 Points, Or 1.43%, To 23255.185. The NASDAQ 100 Fell 399.993 Points, Or 1.55%, To 25338.21. The Nasdaq Biotechnology Index Fell 0.07% To 5913.46. The Philadelphia Semiconductor Index Fell 2.07% To 7966.334. The Philadelphia Stock Exchange KBW Bank Index Rose 0.77% To 171.80. The Dow Jones KBW Regional Bank Index Rose 2.12% To 137.72

Share

Greek Coast Guard Says 14 Migrants Dead After Incident Off Northern Aegean Island Of Chios

TIME
ACT
FCST
PREV
U.S. IHS Markit Manufacturing PMI Final (Jan)

A:--

F: --

P: --

U.S. ISM Output Index (Jan)

A:--

F: --

P: --

U.S. ISM Inventories Index (Jan)

A:--

F: --

P: --

U.S. ISM Manufacturing Employment Index (Jan)

A:--

F: --

P: --

U.S. ISM Manufacturing New Orders Index (Jan)

A:--

F: --

P: --

U.S. ISM Manufacturing PMI (Jan)

A:--

F: --

P: --

US President Trump delivered a speech
South Korea CPI YoY (Jan)

A:--

F: --

P: --

Japan Monetary Base YoY (SA) (Jan)

A:--

F: --

P: --

Australia Building Approval Total YoY (Dec)

A:--

F: --

P: --
Australia Building Permits MoM (SA) (Dec)

A:--

F: --

P: --
Australia Building Permits YoY (SA) (Dec)

A:--

F: --

P: --

Australia Private Building Permits MoM (SA) (Dec)

A:--

F: --

P: --
Australia Overnight (Borrowing) Key Rate

A:--

F: --

P: --

RBA Rate Statement
Japan 10-Year Note Auction Yield

A:--

F: --

P: --

The U.S. House of Representatives voted on a short-term spending bill to end the partial government shutdown.
Saudi Arabia IHS Markit Composite PMI (Jan)

A:--

F: --

P: --

RBA Press Conference
Turkey PPI YoY (Jan)

A:--

F: --

P: --

Turkey CPI YoY (Jan)

A:--

F: --

P: --

Turkey CPI YoY (Excl. Energy, Food, Beverage, Tobacco & Gold) (Jan)

A:--

F: --

P: --

U.K. 10-Year Note Auction Yield

A:--

F: --

P: --

Richmond Federal Reserve President Barkin delivered a speech.
U.S. Weekly Redbook Index YoY

A:--

F: --

P: --

Mexico Manufacturing PMI (Jan)

A:--

F: --

P: --

U.S. API Weekly Refined Oil Stocks

A:--

F: --

P: --

U.S. API Weekly Gasoline Stocks

A:--

F: --

P: --

U.S. API Weekly Cushing Crude Oil Stocks

A:--

F: --

P: --

U.S. API Weekly Crude Oil Stocks

A:--

F: --

P: --

Japan IHS Markit Services PMI (Jan)

--

F: --

P: --

Japan IHS Markit Composite PMI (Jan)

--

F: --

P: --

China, Mainland Caixin Services PMI (Jan)

--

F: --

P: --

China, Mainland Caixin Composite PMI (Jan)

--

F: --

P: --

India HSBC Services PMI Final (Jan)

--

F: --

P: --

India IHS Markit Composite PMI (Jan)

--

F: --

P: --

Russia IHS Markit Services PMI (Jan)

--

F: --

P: --

South Africa IHS Markit Composite PMI (SA) (Jan)

--

F: --

P: --

Italy Services PMI (SA) (Jan)

--

F: --

P: --

Italy Composite PMI (Jan)

--

F: --

P: --

Germany Composite PMI Final (SA) (Jan)

--

F: --

P: --

Euro Zone Composite PMI Final (Jan)

--

F: --

P: --

Euro Zone Services PMI Final (Jan)

--

F: --

P: --

U.K. Composite PMI Final (Jan)

--

F: --

P: --

U.K. Total Reserve Assets (Jan)

--

F: --

P: --

U.K. Services PMI Final (Jan)

--

F: --

P: --

U.K. Official Reserves Changes (Jan)

--

F: --

P: --

Euro Zone Core CPI Prelim YoY (Jan)

--

F: --

P: --

Euro Zone Core HICP Prelim YoY (Jan)

--

F: --

P: --

Euro Zone PPI MoM (Dec)

--

F: --

P: --

Euro Zone HICP Prelim YoY (Jan)

--

F: --

P: --

Euro Zone Core HICP Prelim MoM (Jan)

--

F: --

P: --

Italy HICP Prelim YoY (Jan)

--

F: --

P: --

Euro Zone Core CPI Prelim MoM (Jan)

--

F: --

P: --

Euro Zone PPI YoY (Dec)

--

F: --

P: --

U.S. MBA Mortgage Application Activity Index WoW

--

F: --

P: --

Brazil IHS Markit Composite PMI (Jan)

--

F: --

P: --

Brazil IHS Markit Services PMI (Jan)

--

F: --

P: --

U.S. ADP Employment (Jan)

--

F: --

P: --

The U.S. Treasury Department released its quarterly refinancing statement.
U.S. IHS Markit Services PMI Final (Jan)

--

F: --

P: --

Q&A with Experts
    • All
    • Chatrooms
    • Groups
    • Friends
    ali flag
    200 point ☝️
    EuroTrader flag
    ali
    2300 done
    @alilet me have a quick look at the chats and tell you what I can see technically
    EuroTrader flag
    ali
    eth 2300
    @aliYeahh tht quick spike higher sent it towards 2300 but would it be sustained above that levels?.
    EuroTrader flag
    3531676 flag
    EuroTrader
    @EuroTraderyes
    EuroTrader flag
    EuroTrader
    @aliEth might as well trade towards 2600 before it continues the move to the Downside if it failed to break the resistance
    EuroTrader flag
    3531676
    @Visitor3531676okay mate. Tomorrow i expect gold to continue to the upside after we just had a break outta the accumulation levels
    EuroTrader flag
    3531676
    @Visitor3531676Did you get to see the gold charts i just shared here in the chatroom ?
    ali flag
    before opening market btc and eth go green 💚🍏
    3531676 flag
    EuroTrader
    @EuroTraderwhen this evening
    EuroTrader flag
    3531676
    @Visitor3531676I shared it some few minutes ago. You didn't get to see the charts I shared ?
    EuroTrader flag
    ali
    before opening market btc and eth go green 💚🍏
    @alihopefully it trades this way but in the short term i really doubt that it would open with a greenn
    EuroTrader flag
    favour flag
    @SlowBear ⛅ hey man I want to share something with u on gbpjpy
    3439079 flag
    yes
    EuroTrader flag
    favour
    @SlowBear ⛅ hey man I want to share something with u on gbpjpy
    @favourhello brother. You can share. what's your thoughts on Gbpjpy
    EuroTrader flag
    3439079
    yes
    @Visitor3439079Are you still on Gold. I shared some setups earlier on Gold, did you see them?.
    EuroTrader flag
    EuroTrader flag
    EuroTrader flag
    EuroTrader
    @favouri didn't sleep on this trade and guess what. It's playing out just like iIcalled. Tomorrow is another day we would be active during London sess
    Type here...
    Add Symbol or Code

      No matching data

      All
      Trump Updates
      Recommend
      Stocks
      Cryptocurrencies
      Central Banks
      Featured News
      • All
      • Russia-Ukraine Conflict
      • Middle East Flashpoint
      • All
      • Russia-Ukraine Conflict
      • Middle East Flashpoint
      Search
      Products

      Charts Free Forever

      Chats Q&A with Experts
      Screeners Economic Calendar Data Tools
      Membership Features
      Data Warehouse Market Trends Institutional Data Policy Rates Macro

      Market Trends

      Market Sentiment Order Book Forex Correlations

      Top Indicators

      Charts Free Forever
      Markets

      News

      News Analysis 24/7 Columns Education
      From Institutions From Analysts
      Topics Columnists

      Latest Views

      Latest Views

      Trending Topics

      Top Columnists

      Latest Update

      Signals

      Copy Rankings Latest Signals Become a signal provider AI Rating
      Contests
      Brokers

      Overview Brokers Assessment Rankings Regulators News Claims
      Broker listing Forex Brokers Comparison Tool Live Spread Comparison Scam
      Q&A Complaint Scam Alert Videos Tips to Detect Scam
      More

      Business
      Events
      Careers About Us Advertising Help Center

      White Label

      Broker API

      Data API

      Web Plug-ins

      Affiliate Program

      Awards Institution Evaluation IB Seminar Salon Event Exhibition
      Vietnam Thailand Singapore Dubai
      Fans Party Investment Sharing Session
      FastBull Summit BrokersView Expo
      Recent Searches
        Top Searches
          Markets
          News
          Analysis
          User
          24/7
          Economic Calendar
          Education
          Data
          • Names
          • Latest
          • Prev

          View All

          No data

          Scan to Download

          Faster Charts, Chat Faster!

          Download App
          English
          • English
          • Español
          • العربية
          • Bahasa Indonesia
          • Bahasa Melayu
          • Tiếng Việt
          • ภาษาไทย
          • Français
          • Italiano
          • Türkçe
          • Русский язык
          • 简中
          • 繁中
          Open Account
          Search
          Products
          Charts Free Forever
          Markets
          News
          Signals

          Copy Rankings Latest Signals Become a signal provider AI Rating
          Contests
          Brokers

          Overview Brokers Assessment Rankings Regulators News Claims
          Broker listing Forex Brokers Comparison Tool Live Spread Comparison Scam
          Q&A Complaint Scam Alert Videos Tips to Detect Scam
          More

          Business
          Events
          Careers About Us Advertising Help Center

          White Label

          Broker API

          Data API

          Web Plug-ins

          Affiliate Program

          Awards Institution Evaluation IB Seminar Salon Event Exhibition
          Vietnam Thailand Singapore Dubai
          Fans Party Investment Sharing Session
          FastBull Summit BrokersView Expo

          Companies Move to Refinance Sooner: 'Better Off to Lock It In' — WSJ

          Dow Jones Newswires
          Elanco Animal Health
          -1.62%
          Hovnanian Enterprises Inc. Dep Shr Srs A Pfd
          -0.60%
          Hovnanian Enterprises
          +4.15%
          Savers Value Village
          +2.33%

          By Mark Maurer and Jennifer Williams

          Many companies are jumping on lower interest rates to refinance their debt sooner than later, choosing not to wait for the possibility of further declines as the economy and markets only become more difficult to read.

          Businesses typically replace old debt with new to pay a lower interest rate, change the terms or consolidate debt. The corporate bond market is particularly strong as credit spreads, or the extra yield investors demand to hold them instead of U.S. Treasury bonds, have narrowed to their smallest percentage since the 1990s.

          The Federal Reserve has been cutting interest rates, which encourages corporate borrowing, amid signs of a slowing jobs growth. But fear of volatility — which could send rates spiking — and President Trump's mercurial initiatives have prompted companies to plan more defensively. Companies such as Savers Value Village, Elanco Animal Health and Hovnanian Enterprises are taking liquidity while it is available, rather than waiting closer to the maturity date on their loans.

          Companies are weighing their financing strategies amid fiscal policy uncertainty, inflation, a fight over the Fed's independence, and geopolitical strife in places like Venezuela, Iran and Greenland.

          U.S. corporate-debt refinancings totaled roughly $425 billion in 2025, up 5% from the previous year and the highest level since 2020, according to Dealogic.

          "If you can get out now and do something now, that is 100% the desire," said Amol Dhargalkar, managing partner and chairman at Chatham Financial, adding that companies aren't necessarily borrowing more than they need. "You know what the market is right now. And if you waited, who knows what the world could look like?"

          Savers Value Village pushed out its debt maturity by around four years by refinancing in September. The thrift retailer's executives had planned to take action in the next 12 to 18 months with the debt maturing in 2028, but started considering refinancing last summer because of the appealing market conditions, said CFO Michael Maher.

          "We had a window where our strong credit profile matched up with a really great market," he said. "There was no reason to wait and take the chance that that may not continue to be available again."

          Along with the later maturity, the company now has more favorable spreads on its variable rate, equating to roughly $17 million in annual savings on around $750 million in debt, which the CFO said outweigh the one-time costs of nearly $33 million tied to refinancing early. Savers Value Village also expanded its revolving line of credit by $55 million and can now pay down debt without a penalty thanks to the September transaction.

          Meanwhile, Elanco Animal Health, the Indianapolis-based producer of medicines for pets and livestock, refinanced a $2.1 billion term loan into three new debt facilities in recent months. The debt wasn't due until 2027, but the company sought to push the maturity out as far as possible, Chief Financial Officer Bob VanHimbergen said.

          The changing rates coincided with the company's typical window to refinance before a maturity, making it the right time to act, he said.

          "Because of potential for market volatility with the geopolitical environment, we wanted to hit the market knowing that we were better off to lock it in," VanHimbergen said, referring to political announcements related to things like tariffs and the Fed.

          Hovnanian Enterprises, the Matawan, N.J.-based home builder, refinanced $900 million in senior notes last fall, saving $12 million a year in interest. The company wanted to avoid hefty penalties for paying down its debt early, but also not wait too long and run the risk of facing deteriorating market conditions, CFO Brad O'Connor said.

          Hovnanian hasn't always made the right call, he said. In 2015, the company opted to wait closer to maturity for almost a year because it didn't want to pay a roughly $70 million prepayment penalty. But when the company was ready to refinance, the high-yield market had closed to home builders and other industries, he said.

          "It hurts a little, but we know what happens. If you try to get too cute and too precise on exact timing, you can get caught," O'Connor said.

          Other companies are in the market to refinance.

          Phillips Edison, a Cincinnati-based real-estate investor that owns grocery-anchored shopping centers, expected to refinance up to $400 million on the public debt markets by June, ahead of a 2027 maturity, Chief Financial Officer John Caulfield said.

          The REIT is watching the direction of credit spreads and Treasury rates. But recent reports of lower unemployment claims coupled with an easier pace of inflation, "I think ... shows the tension in the market that exists," Caulfield said.

          "We're going to look this year to find the right appropriate window of stability," he said. "We're trying to figure out if we can get another 10 basis points off or things like that."

          Write to Mark Maurer at mark.maurer@wsj.com and Jennifer Williams at jennifer.williams@wsj.com

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Elanco Animal Health Gets USDA Approval for Canine-Dermatitis Treatment

          Dow Jones Newswires
          Elanco Animal Health
          -1.62%

          By Elias Schisgall

          Elanco Animal Health received approval from the Agriculture Department for Befrena, the company's antibody treatment for canine allergic and atopic dermatitis.

          The animal-medicine company said Wednesday that the injectable treatment is expected to launch in the first half of 2026.

          It said Befrena was the company's second canine-dermatology product to be approved in the past 18 months, joining Zenrelia. The company estimates the size of the canine-dermatology market to be about $1.3 billion.

          "The animal health sector is increasingly focused on antibody-based therapies, and today's approval is an important step forward in delivering high-impact innovation that enhances the quality of life for pets," Ellen de Brabander, Elanco's executive vice president of research and development, said.

          Write to Elias Schisgall at elias.schisgall@wsj.com

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Top Life Sciences Stocks for 2026: BofA Highlights Industry Leaders

          Investing.com
          Apple
          -0.20%
          IQVIA Holdings
          -11.88%
          Advanced Micro Devices
          -1.69%
          Tesla
          +0.04%
          Elanco Animal Health
          -1.62%

          Investing.com -- The life sciences and diagnostic tools sector is poised for growth in 2026, with several companies well-positioned to capitalize on improving market conditions. According to Bank of America’s latest analysis, these companies offer compelling investment opportunities based on innovation, market positioning, and growth potential.

          Get premium news and insight, AI stock picks, and deep research tools by upgrading to InvestingPro - get 55% off today

          Thermo Fisher Scientific emerges as BofA’s top pick within the Life Sciences Tools industry. The bank has raised its price objective to $700 while reiterating a Buy rating. TMO’s management has guided to fiscal year 2026 topline growth of 3-4% and over 50 basis points of operating margin expansion, excluding benefits from the Clario acquisition, which is expected to be 45 cents accretive in year one. The company should benefit from sector tailwinds including reshoring and easing uncertainty in academic, government, and pharmaceutical end-markets. TMO’s innovation and commitment to being the "trusted partner" are expected to drive continued momentum.

          In recent developments, Thermo Fisher Scientific has received several positive analyst ratings, including an upgrade to Overweight from KeyBanc and new Overweight or Buy ratings from Morgan Stanley and Goldman Sachs. The company also announced an expansion of its bioprocessing capabilities across Asia to support the region’s growing biopharmaceutical industry.

          IQVIA Holdings enters 2026 with a more constructive and de-risked setup. Management commentary points to at least similar top-line growth next year (approximately 5% reported), reflecting growing confidence in the demand environment. Decision cycles are shortening, and RFP flow has become more consistent, contributing to a more predictable backdrop despite uneven sector growth. The Technology & Analytics Solutions segment should remain steady, supported by continued customer engagement and adoption of analytics and AI tools. BofA has raised its price objective to $260 and maintains a Buy rating, citing IQV’s strong underlying long-term fundamentals and competitive position in the Phase I-IV space.

          IQVIA Holdings has entered into a strategic collaboration with Amazon Web Services (AWS), designating it as a preferred cloud provider to enhance its AI platform for clinical trials and healthcare analytics. Additionally, Stifel raised its price target on the company, while Morgan Stanley initiated coverage with an Overweight rating.

          Guardant Health is positioned as a logical beneficiary of growth in molecular diagnostic testing, particularly liquid biopsy. The company enters 2026 with strong momentum as legacy offerings like G360 Liquid remain early in their adoption curve. GH stands out with a comprehensive portfolio across the cancer care continuum. Key catalysts include Reveal’s expansion into breast cancer treatments, anticipated FDA approval for G360 Liquid, and accelerating Shield adoption through partnerships. BofA has raised its price objective to $120 and reiterates a Buy rating, seeing potential upside not reflected in current estimates.

          Guardant Health recently expanded its Guardant Reveal blood test to include therapy response monitoring for patients with advanced solid tumors. The company also saw positive analyst actions, with Jefferies raising its price target and BTIG naming it a top pick for 2026.

          Elanco Animal Health is BofA’s top pick within Animal Health coverage, supported by a reinvigorated product portfolio and key launches. Despite sector headwinds from muted veterinary visits and consumer pressures, ELAN’s strong pipeline (including Befrena) and successful launches (Credelio Quattro, Zenrelia) provide a clear path to sustained growth. The company’s insulation from clinic traffic further differentiates it from peers with higher exposure, positioning it to better navigate a challenging macro environment. BofA maintains its price objective at $25.

          Elanco Animal Health received conditional approval from the U.S. Food and Drug Administration for its Credelio Quattro-CA1 product as a treatment for New World screwworm larvae infestations in dogs. The company also continued to receive positive analyst sentiment, with Leerink Partners raising its price target and both Stifel and KeyBanc maintaining their positive ratings.

          This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Elanco Animal Health Is Maintained at Equal-Weight by Morgan Stanley

          Dow Jones Newswires
          Elanco Animal Health
          -1.62%
          This news item displays a headline only and has no other text.
          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Elanco Receives FDA Conditional Approval For Credelio Quattro CA1 To Treat Screwworm In Dogs

          dpa-AFX
          Elanco Animal Health
          -1.62%

          WASHINGTON (dpa-AFX) - Elanco Animal Health Incorporated (ELAN) on Thursday said it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro CA1 for the treatment of infestations caused by New World screwworm larvae in dogs.

          The conditional approval was based on a study evaluating the efficacy of lotilaner, the active ingredient in Credelio Quattro CA1, against New World screwworm. Published in Parasites & Vectors, the study found that oral administration of lotilaner at the minimum recommended dosage was 100% effective against Cochliomyia hominivorax larvae within 24 hours in naturally infested dogs.

          According to the U.S. Department of Agriculture, 14 cases of New World screwworm have been reported within 400 miles of the U.S.-Mexico border, all linked to cattle movement.

          ELAN shares were up more than 2% in pre-market after closing at $22,08, down 1.82%.

          Copyright(c) 2025 RTTNews.com. All Rights Reserved

          Copyright RTT News/dpa-AFX

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Elanco Announces Investment in U.S. Manufacturing and R&D, Driven by Tax, Tariff and Regulatory Clarity

          Acceswire
          Elanco Animal Health
          -1.62%

          NORTHAMPTON, MA / ACCESS Newswire / December 17, 2025 / Elanco announced $400 million in continued investment in its U.S. operations, workforce and communities over the next five years. This deepens Elanco's commitment to product innovation, advanced manufacturing and its customers - farmers, veterinarians and pet owners. The company will expand its R&D presence in its new Indianapolis global headquarters and surrounding OneHealth Innovation District, while continuing to invest in its U.S.-based manufacturing footprint. Elanco will further invest in its Kansas monoclonal antibody (mAb) manufacturing facility to support innovation, particularly a major next generation immuno-therapeutic pet innovation. The U.S. Department of Agriculture (USDA) has granted an accelerated pathway for conditional approval of a novel immuno-therapeutic that has the potential to be a first-in-class major pet health blockbuster, expected in the next 2-3 years.

          Additionally, as part of the positive engagement with the USDA, Elanco announces significant progress in the final steps of the approval of Befrena™, its newest potential blockbuster product. Review of all technical sections and label alignment is now complete, with the final administrative review underway at the USDA. Befrena has demonstrated differentiated efficacy in treating dogs with allergic dermatitis and canine atopic dermatitis. In both laboratory and field studies, Befrena has shown to be safe and well-tolerated, offering a dependable treatment option for veterinary professionals and pet owners alike. Befrena will offer important efficacy, convenience and value differentiators. Elanco continues to expect a first half 2026 launch.

          In connection with these investments, Elanco expects the 2026 net tariff impact to be immaterial to adjusted EBITDA growth, given additional tariff clarity and a positive offset from an incremental price increase.

          The combination of a favorable tax environment from the One Big Beautiful Bill Act, regulatory reform resulting in improved timelines for USDA regulatory reviews and greater certainty on tariffs has created favorable conditions for the continuation of U.S. investments in R&D and manufacturing, while bringing key innovation capabilities from Europe to the U.S.

          Elanco CEO Jeff Simmons joined 'Mornings with Maria' on Fox Business to discuss the $400 million investment in U.S. manufacturing and R&D.

          View additional multimedia and more ESG storytelling from Elanco on 3blmedia.com.

          Contact Info:

          Spokesperson: Elanco

          Website: https://www.3blmedia.com/profiles/elanco

          Email: info@3blmedia.com

          SOURCE: Elanco

          View the original press release on ACCESS Newswire

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Elanco (ELAN) Stock Is Up, What You Need To Know

          Stock Story
          Centene
          -0.68%
          Elanco Animal Health
          -1.62%
          Molina Healthcare
          +0.12%
          Oscar Health
          -0.64%

          What Happened?

          Shares of animal health company Elanco jumped 2.4% in the afternoon session after several top executives, including the CEO and CFO, disclosed significant purchases of company stock, signaling strong internal confidence. 

          Company filings revealed that CEO Jeffrey Simmons acquired shares valued at approximately $478,500, while CFO Robert Vanhimbergen purchased stock worth about $150,426. Another Executive Vice President, Rajeev A. Modi, also bought shares for a total of $95,984. Such purchases by a company's own leadership are often seen by investors as a positive sign about its future prospects. 

          After the initial pop the shares cooled down to $22.23, up 2.4% from previous close.

          Is now the time to buy Elanco? Access our full analysis report here.

          What Is The Market Telling Us

          Elanco’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

          The previous big move we wrote about was 22 days ago when the stock gained 3.5% on the news that reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. 

          These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Centene (CNC) shares jumping as much as 8%, Molina Healthcare (MOH) rising over 3%, and Oscar Health (OSCR) soaring 18%. The potential for a two-year extension reduces regulatory uncertainty for the sector, which investors view as a significant positive for the industry's outlook.

          Elanco is up 84.5% since the beginning of the year, and at $22.23 per share, it is trading close to its 52-week high of $23.43 from November 2025. Investors who bought $1,000 worth of Elanco’s shares 5 years ago would now be looking at an investment worth $742.14.

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share
          FastBull
          Copyright © 2026 FastBull Ltd

          728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG

          TelegramInstagramTwitterfacebooklinkedin
          App Store Google Play Google Play
          Products
          Charts

          Chats

          Q&A with Experts
          Screeners
          Economic Calendar
          Data
          Tools
          Membership
          Features
          Function
          Markets
          Copy Trading
          Latest Signals
          Contests
          News
          Analysis
          24/7
          Columns
          Education
          Company
          Careers
          About Us
          Contact Us
          Advertising
          Help Center
          Feedback
          User Agreement
          Privacy Policy
          Personal Information Protection Statement
          Business

          White Label

          Broker API

          Data API

          Web Plug-ins

          Poster Maker

          Affiliate Program

          Risk Disclosure

          The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

          No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

          Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

          Not Logged In

          Log in to access more features

          Connect Broker
          Become a signal provider
          Help Center
          Customer Service
          Dark Mode
          Price Up/Down Colors

          Log In

          Sign Up

          Position
          Layout
          Fullscreen
          Default to Chart
          The chart page opens by default when you visit fastbull.com